Publications by authors named "Andre P Fay"

42Publications

First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.

Clin Genitourin Cancer 2020 08 4;18(4):244-251.e4. Epub 2020 Mar 4.

Latin American Cooperative Oncology Group, Genito-Urinary Tumors Section, Porto Alegre, Rio Grande do Sul, Brazil; PUCRS, School of Medicine, Porto Alegre, Rio Grande do Sul, Brazil; Grupo Oncoclínicas, Clinical Oncology Department, São Paulo, São Paulo, Brazil; Hospital São Lucas da PUCRS, Oncology Department, Porto Alegre, Rio Grande do Sul, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.02.012DOI Listing
August 2020

PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.

Clin Genitourin Cancer 2020 06 16;18(3):e254-e259. Epub 2019 Oct 16.

PUCRS School of Medicine, Porto Alegre, Brazil; Dana Farber Cancer Institute/Harvard Medical School, Boston, MA; Department of Medical Oncology, Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.10.014DOI Listing
June 2020

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Mol Cancer Ther 2020 02 25;19(2):690-696. Epub 2019 Oct 25.

Cancer Genetics Lab, Division of Pulmonary Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0642DOI Listing
February 2020

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Ann Transl Med 2019 Mar;7(Suppl 1):S7

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.01.37DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462610PMC
March 2019

Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database.

J Glob Oncol 2018 09;4:1-14

Andre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JGO.17.00119
Publisher Site
http://dx.doi.org/10.1200/JGO.17.00119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223429PMC
September 2018

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2017 Dec 2;120:120-126. Epub 2017 Nov 2.

Bladder Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428173048
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2017.10.012DOI Listing
December 2017

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

J Clin Oncol 2016 Oct;34(30):3655-3663

Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Sabina Signoretti, and Toni K. Choueiri, Dana-Farber Cancer Institute; Wanling Xie, Rana R. McKay, Mark A. Preston, Eunyoung Cho, Sabina Signoretti, and Toni K. Choueiri, Brigham and Women's Hospital; Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Eunyoung Cho, David F. McDermott, Sabina Signoretti, and Toni K. Choueiri, Harvard Medical School; Mark A. Preston and Kathryn M. Wilson, Harvard School of Public Health; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Laurence Albiges, Gustave Roussy, Université Paris-Saclay, Villejuif, France; A. Ari Hakimi, Emily C. Zabor, Anders J. Skanderup, and Helena Furberg, Memorial Sloan Kettering Cancer Center, New York; Ronit Simantov and Xun Lin, Pfizer Oncology, New York, NY; Jae-Lyun Lee, University of Ulsan College of Medicine, Asan; Sun-Young Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sandy Srinivas, Stanford Cancer Institute, Stanford; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Georg A. Bjarnason, Sunnybrook Odette Cancer Center, Toronto; Scott Ernst, London Health Sciences Center, London, Ontario; Lori A. Wood, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Daniel Y.C. Heng, Tom Baker Cancer Center; University of Calgary, Calgary, Alberta, Canada; Ulka N. Vaishamayan, Karmanos Cancer Center, Detroit, MI; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Takeshi Yuasa, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Aristotelis Bamias, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; and Eunyoung Cho, The Warren Alpert Medical School of Brown University; Brown University School of Public Health, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065111PMC
October 2016

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2016 08 23;14(4):304-313.e6. Epub 2016 Feb 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.02.007DOI Listing
August 2016

Statins and survival outcomes in patients with metastatic renal cell carcinoma.

Eur J Cancer 2016 Jan 11;52:155-62. Epub 2015 Dec 11.

Department of Medical Oncology, Tom Baker Cancer Center, 1331 29 Street Northwest, Calgary, AB T2N 4N2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.008DOI Listing
January 2016

Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective.

Surg Pathol Clin 2015 Dec;8(4):657-62

Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue (DANA 1230), Boston, MA 02215, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2015.08.001DOI Listing
December 2015

Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?

BJU Int 2015 Oct;116(4):500-1

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.13070DOI Listing
October 2015

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Eur J Cancer 2015 Nov 4;51(17):2580-6. Epub 2015 Sep 4.

Kidney Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, United States; Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049150080
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2015.08.017DOI Listing
November 2015

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.

Cancer Immunol Res 2015 Oct 26;3(10):1158-64. Epub 2015 May 26.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596765PMC
October 2015

Perioperative therapy for muscle invasive bladder cancer.

Hematol Oncol Clin North Am 2015 Apr;29(2):301-18, ix

Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; University Hospital del Mar-IMIM, Barcelona, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588140017
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2014.11.002DOI Listing
April 2015

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

J Immunother Cancer 2015 17;3. Epub 2015 Feb 17.

Dana-Farber Cancer Institute, 450 Brookline Avenue (DANA 1230), Boston, MA 02215 USA ; Brigham and Women's Hospital, 75 Francis Street (Thorn Building 504A), Boston, MA 02215 USA ; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0047-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357210PMC
March 2015

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

Expert Rev Anticancer Ther 2015 Feb 14;15(2):151-6. Epub 2015 Jan 14.

Dana-Farber Cancer Institute, Harvard Medical School 450 Brookline Avenue (DANA 1230), Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1003047DOI Listing
February 2015

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.

BMC Cancer 2014 Aug 15;14:592. Epub 2014 Aug 15.

Centre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, 8 College Road, Singapore 169857, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-592DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148555PMC
August 2014

Adrenocortical carcinoma: the management of metastatic disease.

Crit Rev Oncol Hematol 2014 Nov 4;92(2):123-32. Epub 2014 Jun 4.

Dana-Farber Cancer Institute, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2014.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578298PMC
November 2014

MET as a target in papillary renal cell carcinoma.

Clin Cancer Res 2014 Jul 8;20(13):3361-3. Epub 2014 May 8.

Authors' Affiliations: Dana-Farber Cancer Institute; Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0690DOI Listing
July 2014

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Oncologist 2014 May 22;19(5):507-14. Epub 2014 Apr 22.

Department of Imaging, Dana-Farber Cancer Institute, and Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; Kidney Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012965PMC
May 2014

A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Eur Urol 2014 Sep 16;66(3):529-41. Epub 2014 Mar 16.

Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838140021
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2014.03.003DOI Listing
September 2014

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Clin Cancer Res 2013 Sep 23;19(18):5218-26. Epub 2013 Jul 23.

Authors' Affiliations: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts; GlaxoSmithKline, Collegeville, Pennsylvania; Memorial Sloan-Kettering Cancer Center, New York, New York; and Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522695PMC
September 2013